Basics Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals Inc, formerly Inotek Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. IPO Date: February 18, 2015 Sector: Healthcare Industry: Biotech Market Cap: $353.92M Activated in VL: True Average Daily Range Avg Daily Range: $0.62 | 3.05% Avg Daily Range (30 D): $0.07 | 2.07% Avg Daily Range (90 D): $0.14 | 3.52% Institutional Daily Volume Avg Daily Volume: .72M Avg Daily Volume (30 D): 4.23M Avg Daily Volume (90 D): 4.35M Trade Size Avg Trade Size (Sh.): 89 Avg Trade Size (Sh.) (30 D): 209 Avg Trade Size (Sh.) (90 D): 182 Institutional Trades Total Inst.Trades: 2,678 Avg Inst. Trade: $2.03M Avg Inst. Trade (30 D): $1.1M Avg Inst. Trade (90 D): $1.47M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.33M Avg Closing Trade (30 D): $1.06M Avg Closing Trade (90 D): $1.56M Avg Closing Volume: 131.26K     News Aug 11, 2025 @ 4:00 PM DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offic... Source: Law Offices Of Howard G. Smith Aug 10, 2025 @ 3:38 PM RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR CO... Source: Rosen Law Firm Aug 8, 2025 @ 4:38 PM Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT)... Source: Business Wire Aug 7, 2025 @ 11:45 PM MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & ... Source: Robbins Geller Rudman & Dowd Llp Aug 7, 2025 @ 6:32 PM Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT... Source: Glancy Prongay & Murray Llp Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.62 $-.56 Diluted EPS $-.62 $-.56 Revenue $ $ M $ M Gross Profit $ $ $ Net Income / Loss $ $ -68.92M $ -61.33M Operating Income / Loss $ $ -71.15M $ -64.39M Cost of Revenue $ $ $ Net Cash Flow $ $ -130.81M $ M PE Ratio     Splits Jan 05, 2018:   1:4